Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06124391
Other study ID # PCOS-Subtypes
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2021
Est. completion date December 30, 2025

Study information

Verified date November 2023
Source Shandong University
Contact Zi-jiang Chen
Phone 86-531-85187856
Email chenzijiang@hotmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To classify subtypes of Polycystic Ovary Syndrome (PCOS) using machine-learning algorithms, and compare the reproductive and metabolic characteristics and IVF outcomes across these identified subtypes.


Description:

In this study, we've developed a machine-learning model to classify PCOS patients into four subtypes based on nine clinical characteristics. The goal of this observational study is to: - Learn about different PCOS subtypes using our classification model. - Compare the reproductive and metabolic features of these subtypes. - Assess the outcomes of IVF among different PCOS subtypes. - Prospective 6.5-year follow-up data will be collected. Participants will: - Undergo a telephone interview to gather details on: 1. Current physical stats like height and weight. 2. Reproductive history, including pregnancies and childbirths in recent years. 3. Details about any IVF treatments. 4. Current status of conditions such as PCOS, Type 2 Diabetes, hypertension, and dyslipidemia. - Be invited for a physical examination that includes: 1. Measurements such as height, weight, blood pressure, and body circumferences. 2. Laboratory tests for endocrine and metabolic conditions. 3. Ultrasound scans of the ovaries and liver.


Recruitment information / eligibility

Status Recruiting
Enrollment 50000
Est. completion date December 30, 2025
Est. primary completion date December 30, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - PCOS patients diagnosed using the Rotterdam criteria, which requires the presence of at least two of the following: 1. Menstrual Irregularities: A menstrual cycle length of fewer than 21 days or more than 35 days, and/or fewer than eight cycles per year. 2. Hyperandrogenism: Defined either by an elevated total testosterone level (as per local laboratory criteria) or by a modified Ferriman-Gallwey (mFG) score of 5 or higher. 3. Polycystic Ovaries on Ultrasound: Presence of 12 or more follicles measuring 2-9 mm in diameter in each ovary and/or an ovarian volume exceeding 10 mL. Exclusion Criteria: Patients with congenital adrenal hyperplasias, androgen-secreting tumours, or Cushing's syndrome) will be excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Long-term follow-up
Participants diagnosed with PCOS were not subjected to any specific intervention post-diagnosis. Instead, they were followed up after 6.5 years to assess various outcomes related to PCOS and associated conditions.

Locations

Country Name City State
Brazil Hospital de Clinicas de Porto Alegre Porto Alegre
China Chengdu Jinjiang Maternity and Child Health Hospital Chengdu
China Guangdong Second Provincial General Hospital Guangzhou
China Shandong University Jinan
China Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai
China Tianjin Medical University General Hospital Tianjin
China General Hospital of Ningxia Medical University Yinchuan
Singapore National University Hospital, National University of Singapore Singapore
Sweden Karolinska Institutet Solna
Turkey Hacettepe University School of Medicine Hacettepe Ankara
United States Penn State College of Medicine Hershey Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Shandong University

Countries where clinical trial is conducted

United States,  Brazil,  China,  Singapore,  Sweden,  Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Persistence of PCOS Diagnosis Determining if patients still meet the Rotterdam criteria for a PCOS diagnosis at the follow-up. The hyperandrogenic, ovulatory, and polycystic ovarian conditions at the follow-up time will be assessed. At the 6.5-year follow-up visit.
Primary Changes in PCOS Subtype Tracking if patients have transitioned between different PCOS subtypes at the follow-up. At the 6.5-year follow-up visit.
Primary Body Mass Index Patients' weight (in kilograms) and height (in meters) will be collected and combined to report BMI in kg/m^2 At the 6.5-year follow-up visit.
Primary Non-Alcoholic Fatty Liver Disease (NAFLD) NAFLD will be assessed using abdominal ultrasound. At the 6.5-year follow-up visit.
Primary Hypertension Blood pressure will be assessed, and we will determine if a patient has hypertension, defined as systolic blood pressure (SBP) = 140 mmHg and/or diastolic blood pressure (DBP) = 90 mmHg. At the 6.5-year follow-up visit.
Primary Type 2 Diabetes Mellitus (T2DM) Fasting glucose will be assessed, and we will determine if a patient has T2DM, defined as fasting glucose = 7.0 mmol/l. At the 6.5-year follow-up visit.
Primary Dyslipidemia Defined as the presence of any of the following abnormalities:
Total cholesterol = 5.2 mmol/l
Triglycerides (TG) = 1.7 mmol/l
High-density lipoprotein (HDL) < 1.0 mmol/l
Low-density lipoprotein (LDL) = 3.35 mmol/l
At the 6.5-year follow-up visit.
Primary Total live birth rate Live birth is defined as the delivery of any neonate with signs of life at = 28 weeks of gestation. From the diagnosis of PCOS (at the time of enrollment) until a follow-up period of 6.5 years.
Primary Clinical pregnancy rate Clinical pregnancy is defined as the ultrasound confirmation of at least one intrauterine gestational sac. From the diagnosis of PCOS (at the time of enrollment) until a follow-up period of 6.5 years.
Primary Pregnancy loss rate Pregnancy loss is defined as pregnancies that eventuate in a spontaneous abortion or therapeutic abortion that occurred throughout pregnancy. From the diagnosis of PCOS (at the time of enrollment) until a follow-up period of 6.5 years.
Primary Maternal and neonatal complications Any maternal and neonatal complications, including gestational diabetes, preeclampsia, etc., will be collected. From the diagnosis of PCOS (at the time of enrollment) until a follow-up period of 6.5 years.
See also
  Status Clinical Trial Phase
Completed NCT03142633 - MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
Completed NCT06158932 - A Single Group Study to Evaluate the Effects of a Myo-Inositol and D-Chiro Inositol Supplement on Symptoms Associated With Polycystic Ovary Syndrome and Hormone Imbalance N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Active, not recruiting NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Completed NCT04932070 - Berberine and Polycystic Ovary Syndrome N/A
Suspended NCT03652987 - Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
Completed NCT03480022 - Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS Phase 3
Active, not recruiting NCT03043924 - Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS) N/A
Completed NCT05246306 - Aerobic Capacity and Physical Fitness Level of Adolescents With PCOS
Completed NCT05981742 - Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS Phase 2
Completed NCT05702957 - Letrozole vs Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovarian Syndrome Phase 2/Phase 3
Completed NCT05029492 - Effect of Visceral Manipulation on PCOS N/A
Completed NCT02924025 - Motivational Interviewing as an Intervention for PCOS N/A
Not yet recruiting NCT02255578 - Endobarrier Treatment in Women With PCOS Phase 3
Completed NCT02098668 - Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON N/A
Not yet recruiting NCT00883259 - Metformin and Gestational Diabetes in High-risk Patients: a RCTs Phase 4
Withdrawn NCT01638988 - Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome and a Resistance to Insulin Phase 3
Completed NCT01462864 - Development of a Structured Education Programme for Women With Polycystic Ovary Syndrome N/A
Recruiting NCT01431352 - Letrozole Versus Chinese Herbal Medicine on Polycystic Ovary Syndrome (PCOS) N/A
Completed NCT00989781 - Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome N/A